Neal S. Birnbaum, MD, ACR President Daniel J. Lovell, MD, MPH, and Daniel H. Solomon, MD, MPH, for the ACR Drug Safety Committee members
Kurt Ullman | Issue: June 2007 |
Neal S. Birnbaum, MD, ACR President Daniel J. Lovell, MD, MPH, and Daniel H. Solomon, MD, MPH, for the ACR Drug Safety Committee members
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….
With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…
The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development